SCHEMBL13829037

SCHEMBL13829037

CCCCCCCCCCCCC(O)CNCCCN(CCCNCC(O)CCCCCCCCCC)CCCN(CCCNCC(O)CCCCCCCCCCCC)CCCNCC(O)CCCCCCCCCCCC

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 5/20 0.40
FFAR4 Q5NUL3 1/20 0.39
FFAR1 O14842 1/20 0.39
PLA2G1B P04054 3/20 0.38
PSMD14 O00487 2/20 0.38
MMP2 P08253 2/20 0.38
ATG4B Q9Y4P1 2/20 0.38
HSP90AA1 P07900 1/20 0.38
ANPEP P15144 1/20 0.38
ERAP2 Q6P179 1/20 0.38
RAD52 P43351 1/20 0.38
PLA2G2A P14555 1/20 0.36
KDM5A P29375 2/20 0.36
PHF8 Q9UPP1 2/20 0.36
FAAH O00519 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
EPHX2 P34913 1/20 0.35
PAOX Q6QHF9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12515903 1.00 GPR84 (0.40) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL12515783 1.00 GPR84 (0.40) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL21554930 0.90 GPR84 (0.42) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL25955602 0.90 GPR84 (0.42) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL24045753 0.90 GPR84 (0.42) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL13964577 0.90 L3MBTL1 (0.37) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL13964576 0.90 L3MBTL1 (0.37) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL4602473 0.87 DNM1 (0.45) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL4601959 0.87 DNM1 (0.45) GPR84FFAR4FFAR1PLA2G1BPSMD14
SCHEMBL4602087 0.87 DNM1 (0.45) GPR84FFAR4FFAR1PLA2G1BPSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289584-A1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND COLIPIDS FOR DELIVERING THERAPEUTIC MOLECULES AGAVE PHARMA, INCORPORATED (US) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289584-A1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND COLIPIDS FOR DELIVERING THERAPEUTIC MOLECULES ANXA4, ANXA6, RNASE1 GPR84 1196/4885FFAR4 3728/4885FFAR1 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.